Roche’s tiragolumab flops in another Phase III lung cancer trial

Roche’s struggles with finding a foothold for its immune checkpoint inhibitor tiragolumab the cancer treatment space have been reinforced with the latest failure of the Phase III SKYSCRAPER-01 trial in lung cancer patients.